Atlas Trials

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Clinical trial NCT00398320 · COMPLETED

Trial details

NCT number
NCT00398320
Sponsor
Pamela L. Kunz
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroendocrine Tumors
Start date
2006-11-01
Primary completion
2012-10-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.